• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP:BICX)

0.2010 UNCHANGED
Delayed Quote Updated: 3:23 PM EST, Nov 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 0.2010
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2010
Today's Range 0.2010 - 0.2010
52wk Range 0.1520 - 0.5200
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioCorRx Files Q3 2026 Form 10-Q and Highlights Key Commercial, Clinical, Intellectual Property, and Governance Milestones
November 17, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
BioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory Board
September 10, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

52-Week Range 61.3% below 52-week high
0.2010
0.1552W Low 0.5252W High
1 Week 10.9% below 1-week high
0.201W Low 0.231W High

Biocorrx Inc (BICX) traded between $0.15 and $0.52 over the past 52 weeks and last traded at $0.20, 61.3% below its 52-week high. Over the past week it ranged between $0.20 and $0.23.

Past 12 Months
-4.0%
-19.6%
-19.6%
-47.0%
-31.6%
-37.2%
1W -$0.01
1M -$0.05
3M -$0.05
6M -$0.18
YTD -$0.09
1Y -$0.12

BICX was -37.2% over the past year, -47.0% over six months, -31.6% year to date, -4.0% in the last week.

12 Months vs Market
BICX
-37.2%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months BICX returned -37.2% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 0.00× 3-mo avg
Today 2 3-mo avg 705.0
1W
135.0
1M
826.0
3M
705.0
6M
2.4K
YTD
3.2K
1Y
2.9K

BICX most recently traded 2 shares against a 3-month average daily volume of 705.0.

More News

Read More
News headline image
BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market Supply
August 25, 2026
Via NewMediaWire
Topics Economy
News headline image
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026
Via NewMediaWire
Topics Intellectual Property
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 06, 2026
Via TheNewswire.com
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025
Via TheNewswire.com
Topics Regulatory Compliance
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
November 18, 2025
Via TheNewswire.com
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
January 14, 2026
Via NewMediaWire
News headline image
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 06, 2026
Via NewMediaWire
News headline image
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025
Via NewMediaWire
Topics Regulatory Compliance
News headline image
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
December 10, 2025
From Virtual Investor Conferences; BioCorRx Inc.
Via GlobeNewswire
BioCorRx Reports Business Update for the First Quarter of 2025
May 20, 2025
Via TheNewswire.com
Topics Death
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
December 09, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
November 18, 2025
Via NewMediaWire
News headline image
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
August 14, 2025
Via NewMediaWire
Topics Death
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
August 14, 2025
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Reports Business Update for the First Quarter of 2025
May 20, 2025
Via NewMediaWire
Topics Death
News headline image
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
March 10, 2025
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
March 10, 2025
Via TheNewswire.com
News headline image
BioCorRx Reports Business Update for the Second Quarter of 2024
August 15, 2024
Via NewMediaWire
Topics Intellectual Property
News headline image
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
Via NewMediaWire
Topics Death Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
Via TheNewswire.com
Topics Death Intellectual Property
News headline image
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
Via NewMediaWire
Topics Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
Via TheNewswire.com
Topics Intellectual Property

Frequently Asked Questions

Is Biocorrx Inc publicly traded?
Yes, Biocorrx Inc is publicly traded.
What exchange does Biocorrx Inc trade on?
Biocorrx Inc trades on the OTC Traded
What is the ticker symbol for Biocorrx Inc?
The ticker symbol for Biocorrx Inc is BICX on the OTC Traded
What is the current price of Biocorrx Inc?
The current price of Biocorrx Inc is 0.2010
When was Biocorrx Inc last traded?
The last trade of Biocorrx Inc was at 11/19/26 03:23 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap